Transcat, Inc. (NASDAQ:TRNS) Shares Bought by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC increased its holdings in Transcat, Inc. (NASDAQ:TRNS - Free Report) by 5.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 957,254 shares of the scientific and technical instruments company's stock after buying an additional 52,328 shares during the period. Conestoga Capital Advisors LLC owned about 10.28% of Transcat worth $71,268,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers lifted its holdings in Transcat by 4.1% in the fourth quarter. Rhumbline Advisers now owns 12,348 shares of the scientific and technical instruments company's stock worth $1,306,000 after acquiring an additional 486 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Transcat by 8.5% during the 4th quarter. Principal Financial Group Inc. now owns 5,002 shares of the scientific and technical instruments company's stock worth $529,000 after purchasing an additional 391 shares during the period. Rice Hall James & Associates LLC lifted its holdings in shares of Transcat by 40.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 35,685 shares of the scientific and technical instruments company's stock worth $3,773,000 after purchasing an additional 10,238 shares during the last quarter. Morgan Dempsey Capital Management LLC acquired a new position in Transcat during the 4th quarter valued at approximately $143,000. Finally, Jones Financial Companies Lllp grew its stake in Transcat by 686.7% during the 4th quarter. Jones Financial Companies Lllp now owns 354 shares of the scientific and technical instruments company's stock worth $37,000 after buying an additional 309 shares during the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Transcat from a "sell" rating to a "hold" rating in a research note on Wednesday, May 28th. HC Wainwright reiterated a "buy" rating and issued a $116.00 price objective (up from $106.00) on shares of Transcat in a research report on Wednesday, May 21st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Transcat has an average rating of "Hold" and a consensus target price of $114.00.

Transcat Stock Up 1.8%

Shares of Transcat stock opened at $80.59 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.42 and a quick ratio of 1.98. Transcat, Inc. has a 1-year low of $67.56 and a 1-year high of $147.12. The business's fifty day moving average price is $82.50 and its two-hundred day moving average price is $86.83. The company has a market capitalization of $750.94 million, a P/E ratio of 43.56 and a beta of 0.75.

Transcat (NASDAQ:TRNS - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, missing the consensus estimate of $0.66 by ($0.02). The company had revenue of $77.13 million during the quarter, compared to analyst estimates of $76.40 million. Transcat had a return on equity of 7.23% and a net margin of 6.22%. The firm's quarterly revenue was up 8.8% compared to the same quarter last year. As a group, research analysts forecast that Transcat, Inc. will post 2.3 EPS for the current year.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.